Référentiel des médicaments
Ponatinib
Ponatinib is a medicine in the class oncology. It is used for acute lymphocytic leukemia.
- Classe médicamenteuse: Oncology
- Indications: acute lymphocytic leukemia
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Code ATC
- L01EA05
- Formes courantes
- comprimé
- Dosages courants
- 15 mg
- Interactions connues
- 114 (Majeure: 18 · Modérée: 60 · Mineure: 36)
- Noms commerciaux
- 3
- Pays et marchés
- 3
Indications
Mécanisme d'action
Ponatinib is a kinase inhibitor that inhibits ABL and T315I mutant ABL tyrosine kinase activity in vitro, and also inhibits VEGFR, PDGFR, FGFR, EPH receptor and SRC family kinases, KIT, RET, TIE2 and FLT3.
Posologie adulte habituelle (résumé de la notice)
Newly diagnosed Ph+ ALL: 30 mg orally once daily with chemotherapy; reduce to 15 mg once daily on MRD-negative CR at end of induction; continue up to 20 cycles until loss of response or unacceptable toxicity
Grossesse et allaitement
- Grossesse
- Unsafe Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after.
- Allaitement
- Unsafe No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.
Effets indésirables signalés
- Rash and related conditions
- Arthralgia
- Abdominal pain
- Fatigue
- Headache
- Constipation
Mises en garde encadrées
- Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors. Venous thromboembolic events, heart failure (including fatalities) and hepatotoxicity (liver failure and death) have occurred. Monitor, and interrupt or discontinue based on severity.
Précautions particulières
- Hypertension: monitor blood pressure and manage; interrupt, reduce or stop if not controlled.
- Pancreatitis: monitor serum lipase.
- Myelosuppression: CBC every 2 weeks for first 3 months, then monthly or as indicated.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (114)
- Apalutamide + Ponatinib Major
- Carbamazepine + Ponatinib Major
- Chloramphenicol + Ponatinib Major
- Clarithromycin + Ponatinib Major
- Daunorubicin + Ponatinib Major
- Deferiprone + Ponatinib Major
- Edoxaban + Ponatinib Major
- Enzalutamide + Ponatinib Major
- Eslicarbazepine + Ponatinib Major
- Imatinib + Ponatinib Major
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Ponatinib : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 7 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Ponatinib used for?
Ponatinib is a medicine in the class oncology. It is used for Acute lymphocytic leukemia, Leukemia.
What side effects have been reported with Ponatinib?
Rash and related conditions, Arthralgia, Abdominal pain, Fatigue, Headache, Constipation. Serious warning: Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors.
Can Ponatinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after. Breastfeeding: Unsafe. No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.
What does Ponatinib interact with?
MediHelp lists 114 known interactions for Ponatinib. Major: 18 · Moderate: 60 · Minor: 36. The most serious include Apalutamide, Carbamazepine, Chloramphenicol.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
